Is Pegasys Still Used for Hepatitis C?
No, Pegasys (peginterferon alfa-2a) is no longer a standard or first-line treatment for hepatitis C virus (HCV) infection. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA), updated in 2023, recommend direct-acting antivirals (DAAs) like glecaprevir/pibrentasvir or sofosbuvir/velpatasvir as the primary therapies, which achieve cure rates over 95% with 8-12 weeks of oral treatment.[1] Pegasys, an injectable pegylated interferon often combined with ribavirin, was phased out after DAAs gained approval starting in 2011.
Why Was Pegasys Replaced?
Pegasys had lower efficacy (cure rates of 40-80% depending on genotype and prior treatment) and more side effects like flu-like symptoms, anemia, depression, and thyroid issues compared to DAAs, which are interferon-free and better tolerated.[2] By 2016, the World Health Organization and major regulators endorsed DAAs as preferred, relegating interferon-based regimens to rare historical use.
Are There Any Current Uses for Hepatitis C?
Pegasys sees negligible use for HCV today. It's occasionally referenced in resource-limited settings without DAA access, but even there, global initiatives prioritize generics like sofosbuvir. No major clinical trials or guidelines list it as an option post-2020.[1][3]
What About Other Uses for Pegasys?
Pegasys remains approved and used for chronic hepatitis B in adults and children, often with other antivirals, per FDA labeling.[4] It's also indicated for some cases of hairy cell leukemia.
When Did Key DAAs Get Approved?
| DAA Example | Approval Year | Cure Rate |
|-------------|---------------|-----------|
| Sofosbuvir (Sovaldi) | 2013 | >90% |
| Ledipasvir/sofosbuvir (Harvoni) | 2014 | >95% |
| Glecaprevir/pibrentasvir (Mavyret) | 2017 | >98% pan-genotypic |
These approvals shifted treatment paradigms rapidly.[5]
Pegasys Patent and Availability
Pegasys patent expired in the US in 2015 (US Patent 5,605,699), allowing generics like pegylated interferon alfa-2a injections, though demand for HCV use has evaporated.[6] It's still manufactured by Genentech (Roche) and available via prescription.
Sources
[1]: AASLD-IDSA HCV Guidance
[2]: NEJM: DAA Revolution in HCV
[3]: WHO Hepatitis C Guidelines 2022
[4]: FDA Pegasys Label
[5]: FDA Novel Drugs Timeline
[6]: DrugPatentWatch: Pegasys Patents